To align with the company's strategic development needs and enhance its comprehensive competitiveness, the company has successfully completed the shareholding reform and will be officially renamed "Zhejiang Simai Pharmaceutical Co., Ltd." starting September 29, 2025, marking the entry into a new phase of development.

      Looking ahead, Zhejiang Simai Pharmaceutical Co., Ltd. will continue to uphold the principles of "innovation, pragmatism, and win-win cooperation." With a more refined governance structure and stronger development momentum, the company will accelerate the advancement of its research pipeline and breakthroughs in core technologies, actively seek strategic partnership opportunities, and continuously enhance corporate value.